Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug,... see more

GREY:ATBPF - Post Discussion

View:
Post by Yellowknifer69 on Aug 07, 2020 10:00am

Marketing

Hello and good morning Longs:

Happy Friday!  Hope you are all able to make it a great Day!

Just wanted to chime in on the latest NR.  IMO, companies typically hire external PR firms when they don't have the band width to market their product / services themselves.

On that note I thought Antibe just hired DR. Rami Batal to guide commercial strategy? So there would appear to be a level of redundancy there?

Furthemore, if Antibe has spent the last ten years working diligently to solve a 100 year problem of GI bleeding - then I am fairly certain that every major Pharma is aware that we have solved the problem with Otena?

My experience with big Pharma suggests that this is a very aggressive industry, albeit a small one.  The competition is fierce and no stone goes unturned to get a leg up on your buddy who runs your competitor.  

So, if you are still following my thread - it doesn't really make a huge amount of sense to spend the money to market what everyone already knows.  Just let your all star new commercial guy do that?

Based on that, my bet is that they needed a company that is good at 'encouraging a big pharma to drink the coolaid" because the reaction to Phase 2 has been muted at best? thoughts?

Stay long boys,

Yellowknifer
Comment by MUGMODs on Aug 07, 2020 10:36am
This post has been removed in accordance with Community Policy
Comment by Crunch5555 on Aug 07, 2020 10:42am
where would you like the offers coming from when we are at .45 or in the $ area..that's why we need exposure and a higher SP
Comment by MUGMODs on Aug 07, 2020 11:19am
This post has been removed in accordance with Community Policy
Comment by Doccole on Aug 07, 2020 11:02am
Trying to raise awareness to raise investor interest.  More marketing is good.  Also, 120k isn't junk.  I'm good with this because Canada stocks are normally garbage.  The FDA and Euro meeting is going to be so Huge.  That's what pharma is looking at.   I hope 6 months from now this sucker sells.
Comment by MUGMODs on Aug 07, 2020 11:23am
This post has been removed in accordance with Community Policy
Comment by Doccole on Aug 07, 2020 12:56pm
I've said this before but Dan wants to sell this, and he wants to do a 5/1.  Additionally, he wants to hit the Nasdq and not get crushed.  All these plays build into this strategy.  Like you said- we have to pretend big pharma isn't going to happen. Now that we have potential sales numbers, I would love to find out what they value 346 at? Any models out there?
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities